InvestorsHub Logo
Followers 23
Posts 3662
Boards Moderated 0
Alias Born 01/02/2003

Re: None

Tuesday, 02/05/2019 9:33:12 AM

Tuesday, February 05, 2019 9:33:12 AM

Post# of 60
Flowr Applies for NASDAQ Listing

Toronto, Ontario, Feb. 05, 2019 (GLOBE NEWSWIRE) -- The Flowr Corporation (TSXV: FLWR) (OTC: FLWPF) (“Flowr” or the “Company”), a Canadian licenced producer of premium cannabis products, announced today that it has submitted an application to list its common shares on The NASDAQ Capital Market (“NASDAQ”) and has filed a Form 40-F Registration Statement with the U.S. Securities and Exchange Commission (“SEC”).


The listing of Flowr’s shares on the NASDAQ will be subject to a number of regulatory requirements, including registration of the common shares with the SEC and a determination by the NASDAQ that Flowr has satisfied all applicable listing requirements. Subject to approval for listing, the common shares will continue to trade on the TSX Venture Exchange (TSXV) under FLWR. A trading date will be made public once all regulatory formalities are satisfied.



"Flowr has made tremendous progress executing on its business plan since becoming a public company last year and we believe the Company is well positioned to pursue additional growth opportunities," said Vinay Tolia, Flowr’s Co-CEO. "A NASDAQ listing is an important step forward for Flowr because we believe it will broaden our access to international investors as we become a truly global company."

About Flowr

The Flowr Corporation (TSXV: FLWR) (OTC: FLWPF), through its subsidiaries, holds a cannabis production and sales licence granted by Health Canada. With a head office in Toronto and a production facility in Kelowna, BC, Flowr builds and operates large-scale, GMP-designed cultivation facilities utilizing its own patented growing systems. Flowr’s investment in research and development along with its sense of craftsmanship and a spirit of innovation is expected to enable it to provide premium-quality cannabis that appeals to the adult-use recreational market and addresses specific patient needs in the medicinal market.